NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
|
|
- Ashlie Warren
- 6 years ago
- Views:
Transcription
1 NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following are study notes compiled by the above PGY-5 medical oncology residents and reviewed by a staff medical oncologist. They reflect what we feel is relevant knowledge for graduating medical oncology residents preparing for their final examination. The information has not been surveyed or ratified by the Royal College. WHO CLASSIFICATION OF NON-HODGKIN LYMPHOMA **SUMMARY DOCUMENT FOCUSES ON FOLLICULAR LYMPHOMA**
2 A) PUBLIC HEALTH EPIDEMIOLOGY - Incidence: Second most frequent type of NHL. Accounts for 20-25% of all NHLs. Incidence increases with age. - Mortality: Median survival approximately years RISK FACTORS - Genetic: Small numbers of cases appear to be familial. - Other: N/A B) PRESENTATION & DIAGNOSIS SYMPTOMS & SIGNS - Common Symptoms: Painless peripheral adenopathy in the cervical, axillary, inguinal, and/or femoral regions. Some patients present with asymptomatic abdominal masses or urinary tract obstruction. Approximately 20% present with B symptoms (fever, night sweats, unintentional weight loss). - Common Signs: Lymph node enlargement on CT imaging. INVESTIGATIONS - Laboratory: Lymph node pathology (excisional preferred), CBC and differential, creatinine, electrolytes, liver enzymes, LDH, calcium with albumin, viral screen (Hepatitis B surface antibody, Hepatitis B surface antigen, Hepatitis C antibody, HIV serology) - Diagnostic Imaging: CT of neck/chest/abdomen/pelvis. - Diagnostic Procedures: Bone marrow biopsy and aspirate PATHOLOGY & MOLECULAR BIOLOGY - Common Histology: Nodular growth pattern on histology with effacement of normal lymphoid architecture. Presence of follicle center cells with mixture of centrocytes and centroblasts. - Immunophenotype: Presence of B cell markers. Positive for B cell antigens (CD19, CD20, CD79a, CD21, and CD10). Positive expression of surface immunoglobulin with light chain restriction. Negative for CD5, CD11c, CD23. Cytoplasmic Bcl-2 protein positive. - Relevant Cytogenetics: Cytogenetics show presence of t(14;18). - Relevant Molecular Biology: Evaluation of clonal immunoglobulin gene rearrangements and IgH/bcl2 fusion gene. STAGING - Ann Arbor Staging: Stage Description I Involvement of a single lymph node region or a single extranodal site II Involvement of two or more lymph node regions on the same side of the diaphragm III Involvement of lymph node regions on both sides of the diaphragm IV Diffused/disseminated involvement of one or more extra lymphatic organs or tissues with or without associated lymph node involvement Other B Symptoms: absence (A) or presence (B) or fever >38.5 C, drenching night sweats, and/or unexplained weight loss of >10% body weight in past 6 months E: Extranodal disease X: Bulky disease. Defined as mediastinal mass >1/3 thoracic diameter or any nodal mass >10cm in maximal diameter
3 TUMOR GRADING - Follicular lymphoma is classified into the following 3 histologic grades: o Grade 1: Low grade. 0-5 centroblasts per high power field (HPF) o Grade 2: Low grade centroblasts per HPF o Grade 3: >15 centroblasts per HPF Grade 3 further divided into 3A and 3B. 3B has presence of sheets of centroblasts and no centrocytes. 3B is treated as a high grade lymphoma. PROGNOSIS - The Follicular Lymphoma International Prognostic Index (FLIPI). Pre-dated Rituximab Chemotherapy Factors # of Factors Prognosis 5 year OS 10 year OS Age Good 90% 71% Nodal area >4 Elevated LDH 2 Intermediate 78% 51% Stage III/IV Hb < Poor 53% 36% - The Follicular Lymphoma International Prognostic Index (FLIPI2). Factors # of Factors Risk 3 year OS 5 year OS Age >60 0 Good 91% 80% Marrow involvement Increased B2M 1-2 Intermediate 69% 51% Hb<120 Node >6cm 3-5 Poor 51% 19% C) TREATMENT LOCALIZED FOLLICULAR LYMPHOMA (Stage IA or Contiguous Stage IIA) - Goals of Therapy: To achieve effective and durable disease control with minimal toxicity and maintain quality of life. - Bottom Line General Approach: Involved field radiation therapy (IFRT) is considered standard of care. Consider observation if potential toxicity of IFRT outweighs potential benefits. - Important Phase III Clinical Trials: Reduced dose radiotherapy for local control in non-hodgkin lymphoma: a randomised phase III trial Lowry et al. Radiother Oncol. 2011; 100(1): Regimen Low dose 24Gy in 12 fractions vs Standard dose 40-45Gy in fractions Primary Endpoint ORR Patients with any histological subtype of NHL. Indolent predominantly follicular and marginal zone lymphoma. Size (N) 289 patients with indolent NHL (59% with FL grade 1/2) Results ORR: 92% low dose vs 93% standard dose No difference in local control, remission duration or overall survival Trend towards reduced toxicity in low dose arms In a large randomised trial, there was no loss of efficacy associated with radiotherapy doses of 24Gy in indolent NHL compared with previous standard doses of 40-45Gy
4 ADVANCED STAGE FOLLICULAR LYMPHOMA - for initiating treatment of FL o for initiation of chemoimmunotherapy should be based on the identification of symptoms defined by the GELF (Groupe pour l Etude de Lymphome Folliculaire) criteria. If any of the following are present: A tumor >7cm in diameter 3 nodes in 3 distinct areas, each >3cm in diameter Symptomatic spleen enlargement >16 on CT Organ compression Ascites or pleural effusion Presence of systemic symptoms Serum LDH or beta2-microglobulin levels greater than normal Hb value 100, neutrophil count 1.5, platelet count 100 o Clinical assessments every 3-6 months - Bottom Line General Approach o For symptomatic advanced stage disease (Grade 1,2, 3a), recommended therapy involves 6 cycles bendamustine-rituximab (BR) chemoimmunotherapy followed by 2 years of maintenance rituximab (rituximab every 3 months for total of 8 doses). o For Grade 3b follicular lymphoma, recommended therapy involves 6 cycles R-CHOP chemoimmunotherapy. Maintenance rituximab has not been proven effective following R- CHOP. - Important Phase III Clinical Trials: Chemoimmunotherapy studies Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open label, multicenter, randomised, phase 3 non-inferiority trial. The StIL Study Rummel et al. Lancet. 2013;381: Regimen Bendamustine & Rituximab (BR) vs R-CHOP Primary Endpoint PFS Age >18, ECOG 0-2, newly diagnosed stage III or IV indolent or mantle cell lymphoma Size (N) 499 patients (54% had follicular lymphoma) Results PFS: 69.5mo BR vs 31.2mo RCHOP No significant differences in ORR or OS between treatments BR better tolerated than RCHOP with lower rates of alopecia, infections, peripheral neuropathy, and stomatitis In patients with previously untreated indolent lymphoma, BR can be considered as a preferred 1 st line treatment approach to RCHOP because of increased PFS and fewer toxic effects
5 Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study Flinn et al. Blood. 2014; 123: Regimen Primary Endpoint Size (N) Results Bendamustine & Rituximab (BR) vs R-CHOP/R-CVP Complete Response rate Newly diagnosed indolent NHL or mantle cell lymphoma. Age >18, ECOG patients (70% had follicular lymphoma) BR vs RCHOP/RCVP Complete Response: 31% vs 25% ORR: 97% vs 91% OS and PFS were not assessed Incidence of vomiting and drug hypersensitivity reaction higher in BR arm. Incidence of peripheral neuropathy/paresthesia and alopecia higher in RCHOP/RCVP arm These data indicate BR is noninferior to standard therapy with regard to clinical response with an acceptable safely profile Maintenance Rituximab Studies Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial Salles et al. Lancet 2010; 377:42-51 Regimen Primary Endpoint Patients who responded to 1 st line treatment with chemoimmunotherapy were randomized to 2 years Rituximab maintenance (375mg/m 2 IV q8wks) vs Observation PFS Previously untreated follicular lymphoma (grade 1,2, or 3a) needing systemic therapy. Age > patients Size (N) Results PFS: 74.9% Rituximab vs 57.6% Observation. Risk of progression reduced by 45% At 2 years, Rituximab group had significantly higher CR rates than observation. 71.5% vs 52.5% OS did not differ significantly between groups (HR 0.87) 2 years of rituximab maintenance therapy after immunochemotherapy as first line treatment for follicular lymphoma significantly improves PFS.
6 RELAPSED THERAPY FOR FOLLICULAR LYMPHOMA - Bottom Line General Approach o Relapse with both indolent or aggressive histology (histologic conversion) may occur. Therefore, biopsy for histological confirmation and re-staging should be performed if suggestive of aggressive transformation (ie) rapid growth or discordant growth between various disease sites. o Therapeutic recommendations for relapsed follicular lymphoma requires consideration of various factors as outlined below: Patient Factors Disease Factors Age Comorbidities Symptoms Goals of therapy / patient wishes Acceptance of risks/toxicities of treatment relative to potential benefit Stage Sites of involvement Grade Transformation Prior therapy Time from prior therapy (disease free interval) o Therapy should be individualized. Options include: Age <70 and no comorbidities Age <70 with comorbidities or >70? Palliative symptomatic care Consider high dose chemotherapy and autologous stem cell transplantation especially if early relapse after first line therapy Consider repeating initial treatment regimen especially if achieved initial remission greater than 5 years. Otherwise consider non-cross resistant combination chemotherapy for second line therapies (Rbendamustine, R-CVP, R-CHOP, R-fludarabine, etc.). Consider palliative involved field radiotherapy 4Gy in 2 fractions D) REFERENCES 1. Alberta Health Services Guidelines 2. UptoDate 3. Canadian Cancer Society 4. Odette Cancer Centre Guidelines 5. Lymphoma Canada
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationHODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)
HODGKIN LYMPHOMA Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff
More informationClinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages)
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for relapsed indolent non-hodgkin s lymphoma (all ages) Reference: NHS England 1607 1 First published: TBC Prepared by NHS England
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationHow to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma
How to Refine Treatment Choice in Follicular Lymphoma: From Low-Tumor Burden to High-Risk Follicular Lymphoma Peter A. Riedell, MD and Brad S. Kahl, MD Abstract Follicular lymphoma (FL) is the most common
More informationCPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults The Benefits of the Proposition
More informationFollicular Lymphoma 2016:
Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual
More informationFollicular Lymphoma. Michele Ghielmini. Oncology Institute of Southern Switzerland Bellinzona
Follicular Lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland Bellinzona Conflicts of interest Astra Zeneca Roche Cellgene Mundipharma Janssen Gilead Bayer Abbvie FL remains an incurable
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationNon-Hodgkin Lymphoma in Clinically Difficult Situations
Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationReviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto)
CLL Updated March 2017 by Doreen Ezeife Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr. Matt Cheung (Staff Hematologist, University of Toronto) DISCLAIMER: The following
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationHead and Neck: DLBCL
Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD
More informationSolomon Graf, MD February 22, 2013
Solomon Graf, MD February 22, 2013 Case Review of FL pathology, prognosis Grading of FL Grade 3 disease High proliferative index in grade 1/2 disease Pediatric FL Future of FL classification 57 yo man
More informationLymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital
Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital Function of the Lymph System Lymph Node Lymphocytes B-cells develop in the bone marrow and influence the immune
More informationReference: NHS England 1605
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of advanced indolent non- Hodgkin s lymphoma (all ages) Reference: NHS England 1605 First published: TBC
More informationClinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of mantle cell lymphoma. Reference: NHS England 1630
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of mantle cell lymphoma Reference: NHS England 1630 1 First published: TBC Prepared by NHS England Specialised
More informationNHS England. Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma
NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma NHS England Evidence review: Bendamustine with Rituximab for relapsed low-grade Non- Hodgkin s Lymphoma
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationNotification to Implement Issued by pcodr: December 14, 2012
PROVINCIAL FUNDING SUMMARY Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory) perc Recommendation: Recommends For further
More informationIl trattamento del Linfoma Follicolare in prima linea
Il trattamento del Linfoma Follicolare in prima linea Dr.ssa Carola Boccomini SC Ematologia Dr. U. Vitolo AO Città della Salute e della Scienza Torino, Italy Median follow-up 3 years Median follow-up 6
More information1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page
COME HOME Non-Hodgkin pathway development worksheet, v6 September 2014 1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes
More informationPanel Discussion/References
Follicular Lymphoma (FOLL) FOLL-B category designation for first-line therapy options for FL: Bendamustine + rituximab RCHOP RCVP Submission from Genentech to review the data related to obinutuzumab for
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma August 30, 2018
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Obinutuzumab (Gazyva) for Follicular Lymphoma August 30, 2018 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationClinical Commissioning Policy: Bendamustine with rituximab for first line treatment of mantle cell lymphoma (all ages)
Clinical Commissioning Policy: Bendamustine with rituximab for first line treatment of mantle cell lymphoma (all ages) NHS England Reference: 17088P NHS England INFORMATION READER BOX Directorate Medical
More informationClinical commissioning policy: Bendamustine with rituximab for first line treatment of advanced indolent non-hodgkin s lymphoma (all ages)
Clinical commissioning policy: Bendamustine with rituximab for first line treatment of advanced indolent non-hodgkin s lymphoma (all ages) NHS England Reference: 170055P 1 NHS England INFORMATION READER
More informationLymphoma 101. Nathalie Johnson, MDPhD. Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University
Lymphoma 101 Nathalie Johnson, MDPhD Division of Hematology Jewish General Hospital Associate Professor of Medicine, McGill University Disclosures Consultant and Advisory boards for multiple companies
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationLymphoma: The Basics. Dr. Douglas Stewart
Lymphoma: The Basics Dr. Douglas Stewart Objectives What is lymphoma? How common is it? Why does it occur? How do you diagnose it? How do you manage it? How do you follow patients after treatment? What
More informationIntended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with Indolent lymphoma
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with Indolent lymphoma AA Cancer Centre All patients with a potential or confirmed lymphoproliferative
More informationMedcenter One Cancer Committee 2011 Annual Report
Medcenter One Cancer Committee 211 Annual Report With a Focus on Non-Hodgkin s Lymphoma 21 CND Cancer Registry Statistics Medcenter One Health Systems is proud to be recognized as an accredited cancer
More informationChoice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma
Choice of upfront treatment in the management of diffuse large B-cell lymphoma and follicular lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Bendamustine (Treanda) for Non-Hodgkin Lymphoma November 29, 2012
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bendamustine (Treanda) for Non-Hodgkin Lymphoma November 29, 2012 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationLYMPHOMA DIAGNOSIS and PROGNOSIS. LC Lim Dept of Hematology Singapore General Hospital
LYMPHOMA DIAGNOSIS and PROGNOSIS LC Lim Dept of Hematology Singapore General Hospital OUTLINE Accurate diagnosis Define subtype : WHO classification Staging : Defines extent of involvement Prognosis Determining
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationRituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab for the first-line treatment of stage III-IV (review of guidance 110) Issued: January 2012 guidance.nice.org.uk/ta243 NICE has accredited the process used by the Centre for Health Technology
More informationCLL: disease specific biology and current treatment. Dr. Nathalie Johnson
CLL: disease specific biology and current treatment Dr. Nathalie Johnson Disclosures Consultant and Advisory boards Roche, Abbvie, Gilead, Jansson, Lundbeck,Merck Research funding Roche, Abbvie, Lundbeck
More informationRituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma
Page 1 of 5 Home Search Study Topics Glossary Search Full Text View Tabular View No Study Results Posted Related Studies Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's
More informationThe Lymphomas. An overview..
The Lymphomas An overview.. Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON The lymphomas are an important part of the history of medicine 1666 Magpighi publishes first recorded
More informationPatient Case Studies & Panel Discussion
Patient Case Studies & Panel Discussion Panelists: Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center; Ranjana H. Advani, MD, Stanford Cancer Institute; Andrew D. Zelenetz, MD, PhD, Memorial
More informationeastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning
Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationPan-London Haemato-Oncology Clinical Guidelines. Lymphoid Malignancies Part 3: Follicular Lymphoma
Pan-London Haemato-Oncology Clinical Guidelines Lymphoid Malignancies Part 3: Follicular Lymphoma September 2018 CONTENTS Contents 1 Introduction... 3 2 Early Diagnosis and Prevention... 3 3 Referral Pathways
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationBendamustine for relapsed follicular lymphoma refractory to rituximab
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for relapsed follicular lymphoma refractory to rituximab Bendamustine for relapsed follicular lymphoma refractory to rituximab Contents Summary 1
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationREGISTRATION FORM 1 / 2
IDENTIFICATION AND BASELINE DATA REGISTRATION FORM 1 / 2 M Patient s initials: Sequential case N : SEX : F Date of birth: Place of birth I I Centre I I Address I I Telephone number I I Actual profession
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationRadiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2
Radiation and Hodgkin s Disease: A Changing Field Sravana Chennupati Radiation Oncology PGY-2 History of Present Illness 19 yo previously healthy male college student began having pain in his R shoulder
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationAggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017
Aggressive NHL and Hodgkin Lymphoma Dr. Carolyn Faught November 10, 2017 What does aggressive mean? Shorter duration of symptoms Generally need treatment at time of diagnosis Immediate, few days, few weeks
More informationChallenges in the Treatment of Follicular Lymphoma
Challenges in the Treatment of Follicular Lymphoma Prof. Michele Ghielmini Clinical Director Oncology Institute of Southern Switzerland Bellinzona ESMO guidelines 2014 (simplified) Low tumor burden High
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationPatient underwent hemicolectomy: 7 x 4.5 cm intusscepted segment of ileum in colon - mucosal
Extranodal Lymphomas Rena Buckstein Odette Cancer Center Case: JT 69 yo male COO software company PMHx: basal cell back, cholesterol Presents to ER with severe abdominal pain, bloody diarrhea x 2d In ER
More informationMantle cell lymphoma An update on management
Mantle cell lymphoma An update on management Dr Kim Linton Consultant Medical Oncologist The Christie NHS Foundation Trust 6 th October 2016 This educational meeting is organised and sponsored by Janssen-Cilag
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationChange Summary - Form 2018 (R3) 1 of 12
Summary - Form 2018 (R3) 1 of 12 Form Question Number (r3) Type Description New Text Previous Text Today's date was removed 2018 N/A Today's Date Removed from Key Fields 2018 N/A HCT Type 2018 N/A Product
More informationLow grade Non-Hodgkin Lymphoma: New Therapies & Updates
Low grade Non-Hodgkin Lymphoma: New Therapies & Updates Craig A. Portell MD Assistant Professor of Medicine ivision of Hematology/Oncology University of Virginia Friday, April 28, 2017 Disclosures I have
More informationMEETING SUMMARY ASH 2018, San Diego, USA
MEETING SUMMARY ASH 2018, San Diego, USA Prof. Stefano Luminari University of Modena and Reggio Emilia, Italy AN UPDATE ON PROGNOSTIC FACTORS IN INDOLENT LYMPHOMAS 2 DISCLAIMER Please note: The views expressed
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationClinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages)
Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: 170029P 1 NHS England INFORMATION READER BOX Directorate Medical
More informationAddition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial
Addition of Rituximab to Fludarabine and Cyclophosphamide in Patients with CLL: A Randomized, Open-Label, Phase III Trial Hallek M et al. Lancet 2010;376:1164-74. Introduction > In patients with CLL, the
More informationA CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey
A CASE OF PRIMARY THYROID LYMPHOMA Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey 38 year old female She recognized a mass in her right neck
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationObinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma
Obinutuzumab in combination with bendamustine for treating rituximab-refractory follicular lymphoma 1 st Appraisal Committee meeting Background and Clinical Effectiveness Committee A Lead team John Watkins
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationLymphomas in Prof Paul Ruff Division of Medical Oncology
Lymphomas in 2010 Prof Paul Ruff Division of Medical Oncology Most Common Lymphomas: ~90% B-cell and ~10% T-cell T lymphoblastic: 2% Marginal zone, nodal: 2% Other: 9% Burkitt: 2% Anaplastic large cell:
More information